Biotech proved a surprisingly bright spot in 2022’s startup correction
While not totally immune to 2022’s market correction, biotech fundraising proved to be more resilient than other sectors.
Biotech proved a surprisingly bright spot in 2022’s startup correction by Rebecca Szkutak originally published on TechCrunch